



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 April 2013
EMA/CHMP/265512/2013
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Kinzalmono

telmisartan

On 25 April 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Kinzalmono. The marketing authorisation holder for this medicinal product is Bayer Pharma AG. They may request a re-examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a new contraindication as follows:

The concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment ($\text{GFR} < 60 \text{ ml/min/1.73 m}^2$) (see sections 4.2, 4.4, 4.5).

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full contraindication(s) for Kinzalmono will be as follows²:

- Hypersensitivity to any of the active substances or to any of the excipients listed in section 6.1.
- Hypersensitivity to other sulphonamide-derived substances (since hydrochlorothiazide is a sulphonamide-derived medicinal product).
- Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
- Cholestasis and biliary obstructive disorders.
- Severe hepatic impairment.
- Severe renal impairment (creatinine clearance $< 30 \text{ ml/min}$).
- Refractory hypokalaemia, hypercalcaemia.

The concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment ($\text{GFR} < 60 \text{ ml/min/1.73 m}^2$) (see sections 4.2, 4.4, 4.5).

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion.

² The text in bold represents the new or the amended contraindication.

